Multicenter Phase Ii Study of Moderate Low-Dose Radiotherapy in Indolent Non-Hodgkin Lymphoma: CLCG-iNHL-01 Protocol

作者：Linrui Gao, Xinyue Wang, Changfa Xia, Yong-Wen Song, Liang Wang, Xin Li, Yong Yang, Jianzhong Cao, Ke Chen, Qiuzi Zhong, Yuyan Gao, Shengyu Zhou, Xiaoli Feng, Xiaojun Wang, Ye‐Xiong Li, Shu-Nan Qi · 发表于：Future Oncology · 年份：2024 · DOI：10.2217/fon-2023-0761 · 被引用次数：5 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Viral-associated cancers and disorders

Background: Radiotherapy is an effective treatment for indolent non-Hodgkin lymphoma (iNHL); however, the optimal radiotherapy dose remains to be determined. We hypothesize that a suitable dose may exist between 4 and 24 Gy. Methods: This prospective multicenter phase II trial intends to recruit 73 sites of iNHL patients, who will receive involved-site radiotherapy of 12 Gy in four fractions. The primary objective is the 6-month clinical complete response rate. Tumor tissue, blood and conjunctival specimens will be collected to identify potential predictive biomarkers. Discussion: The CLCG-iNHL-01 trial will evaluate the efficacy and toxicity of 12 Gy in patients with iNHL and provide information on a novel hypofractionation regimen of low-dose radiotherapy. Clinical Trial Registration: NCT05543070 (ClinicalTrials.gov)